MX352604B - Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah. - Google Patents

Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.

Info

Publication number
MX352604B
MX352604B MX2013013277A MX2013013277A MX352604B MX 352604 B MX352604 B MX 352604B MX 2013013277 A MX2013013277 A MX 2013013277A MX 2013013277 A MX2013013277 A MX 2013013277A MX 352604 B MX352604 B MX 352604B
Authority
MX
Mexico
Prior art keywords
hendra
immunogenic compositions
nipah virus
glycoprotein
glycoprotein immunogenic
Prior art date
Application number
MX2013013277A
Other languages
English (en)
Other versions
MX2013013277A (es
Inventor
Elhay Martin
C Broder Christopher
Huang Jin-An
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of MX2013013277A publication Critical patent/MX2013013277A/es
Publication of MX352604B publication Critical patent/MX352604B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La presente invención se refiere a composiciones inmunogénicas de los virus Hendra y Nipah y métodos de uso de las mismas. La invención también se relaciona con métodos para diferenciar sujetos vacunados con las composiciones inmunogénicas de la invención de aquellos infectados con los virus Hendra y/o Nipah.
MX2013013277A 2011-05-13 2012-05-14 Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah. MX352604B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485992P 2011-05-13 2011-05-13
PCT/US2012/037839 WO2012158643A1 (en) 2011-05-13 2012-05-14 Hendra and nipah virus g glycoprotein immunogenic compositions

Publications (2)

Publication Number Publication Date
MX2013013277A MX2013013277A (es) 2014-09-22
MX352604B true MX352604B (es) 2017-11-30

Family

ID=47177303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013277A MX352604B (es) 2011-05-13 2012-05-14 Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.

Country Status (18)

Country Link
US (1) US20150050305A1 (es)
EP (2) EP2707025B8 (es)
JP (4) JP2014516955A (es)
KR (2) KR20200040899A (es)
CN (2) CN110680913A (es)
AU (2) AU2012256000B2 (es)
BR (1) BR112013029309A8 (es)
CA (1) CA2836098C (es)
CL (1) CL2013003248A1 (es)
CO (1) CO6940373A2 (es)
ES (2) ES2963147T3 (es)
HK (1) HK1247833A1 (es)
MX (1) MX352604B (es)
PT (1) PT2707025T (es)
RU (1) RU2681529C2 (es)
UA (1) UA114086C2 (es)
WO (1) WO2012158643A1 (es)
ZA (1) ZA201308701B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035250A1 (en) 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
KR101821680B1 (ko) 2010-07-22 2018-01-24 길리애드 사이언시즈, 인코포레이티드 파라믹소비리대 바이러스 감염을 치료하기 위한 방법 및 화합물
ES2764079T3 (es) * 2011-05-27 2020-06-02 Boehringer Ingelheim Animal Health Usa Inc Vacunas genéticas contra el virus Hendra y el virus Nipah
CN105530956A (zh) * 2013-09-05 2016-04-27 硕腾服务有限责任公司 Hendra和Nipah病毒G糖蛋白免疫原性组合物
NZ733383A (en) * 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
EP3082856A1 (en) * 2013-12-16 2016-10-26 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
HRP20220740T1 (hr) 2015-09-16 2022-11-11 Gilead Sciences, Inc. Postupci za liječenje virusnih infekcija arenaviridae
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
EP3595672B1 (en) 2017-03-14 2023-09-06 Gilead Sciences, Inc. Compounds for use in methods of treating feline coronavirus infections
CN108624602B (zh) * 2017-03-24 2020-10-16 华中农业大学 一株具有阻断活性的抗尼帕病毒g蛋白的单克隆抗体及其应用
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
KR20200090836A (ko) * 2017-12-20 2020-07-29 조에티스 서비시즈 엘엘씨 Hendra 및 Nipah 바이러스 감염을 대비한 백신
CN110951922A (zh) * 2019-12-25 2020-04-03 中国动物卫生与流行病学中心 一种检测亨德拉病毒的raa引物探针及检测方法
CN114641299A (zh) 2020-01-27 2022-06-17 吉利德科学公司 用于治疗SARS CoV-2感染的方法
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
AU2021281351A1 (en) 2020-05-29 2023-01-19 Gilead Sciences, Inc. Remdesivir treatment methods
BR112022026321A2 (pt) 2020-06-24 2023-01-17 Gilead Sciences Inc Análogos de 1'-ciano nucleosídeo e usos dos mesmos
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
WO2022270656A1 (ko) * 2021-06-24 2022-12-29 진철 금 나노입자를 유효성분으로 포함하는 니파 바이러스의 예방 또는 치료용 조성물
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN116751266B (zh) * 2023-06-29 2024-08-20 中国人民解放军军事科学院军事医学研究院 一种亨尼帕病毒保护性抗原及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
CN1882704A (zh) * 2003-09-22 2006-12-20 巴斯德研究院 尼帕病毒检测方法和提供抗汉尼巴病毒的免疫保护的方法
WO2005028673A1 (en) * 2003-09-22 2005-03-31 Institut Pasteur A method for detecting nipah virus and method for providing immunoprotection against henipaviruses
WO2006085979A2 (en) * 2004-07-09 2006-08-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus g glycoprotein
EP1861424B1 (en) 2005-03-14 2011-03-30 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Human monoclonal antibodies against hendra and nipah viruses
DK1881845T3 (da) * 2005-04-25 2010-06-07 Merial Ltd Nipah-virusvacciner
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof

Also Published As

Publication number Publication date
US20150050305A1 (en) 2015-02-19
RU2019104307A (ru) 2019-04-15
JP2014516955A (ja) 2014-07-17
ES2963147T3 (es) 2024-03-25
CN110680913A (zh) 2020-01-14
JP2019142909A (ja) 2019-08-29
CO6940373A2 (es) 2014-05-09
BR112013029309A2 (pt) 2017-06-20
KR20200040899A (ko) 2020-04-20
ZA201308701B (en) 2015-08-26
AU2012256000B2 (en) 2017-05-11
JP2017193537A (ja) 2017-10-26
PT2707025T (pt) 2017-08-31
EP2707025B1 (en) 2017-07-12
JP2018030862A (ja) 2018-03-01
UA114086C2 (xx) 2017-04-25
EP2707025B8 (en) 2017-08-23
EP3251692A1 (en) 2017-12-06
CL2013003248A1 (es) 2014-08-08
WO2012158643A1 (en) 2012-11-22
RU2681529C2 (ru) 2019-03-07
HK1247833A1 (zh) 2018-10-05
KR20140053906A (ko) 2014-05-08
RU2013155470A (ru) 2015-06-20
NZ617722A (en) 2016-03-31
AU2017213501A1 (en) 2017-08-31
EP2707025A4 (en) 2014-12-17
ES2639122T3 (es) 2017-10-25
AU2012256000A1 (en) 2013-12-12
CN104244974A (zh) 2014-12-24
CA2836098A1 (en) 2012-11-22
CA2836098C (en) 2022-06-21
BR112013029309A8 (pt) 2018-01-23
MX2013013277A (es) 2014-09-22
JP6898024B2 (ja) 2021-07-07
EP3251692B1 (en) 2023-09-27
EP2707025A1 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
MX352604B (es) Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
EP4233898A3 (en) Influenza mrna vaccines
PH12016502468A1 (en) Influenza virus vaccines and uses thereof
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
PH12015501156A1 (en) Pharmaceutical compositions
EA201391515A1 (ru) Инактивированная вакцина вируса денге
PH12016500960A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
IN2014KN02769A (es)
EA201290956A1 (ru) Вакцина против вич
WO2013006569A3 (en) Herpes virus vaccine and methods of use
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
WO2011079073A3 (en) Herpes simplex virus vaccines
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
BR112016022214A2 (pt) rnase para uso no tratamento ou prevenção de infecções virais
SG11201706342PA (en) An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
WO2014210082A3 (en) Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
WO2014065848A3 (en) Compounds for treating papilloma virus infection

Legal Events

Date Code Title Description
FG Grant or registration